Hua Medicine Ltd. logo

Hua Medicine Ltd.

Hua Medicine is a leading clinical-stage, innovative drug development company in China, focusing on novel therapies for the treatment of diabetes and CNS disorders.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”2552.HK” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.huamedicine.com
Founded
Disease Focus
Development Stage
STOCK CODEHKG: 2552
Address
275 Ai Di Sheng Road Zhangjiang Hi-Tech Park, 201203
Pudong
China
Email
Contact Number
+852-2338-0852

Hua Medicine is a leading clinical-stage, innovative drug development company in China, focusing on novel therapies for the treatment of diabetes and CNS disorders.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/hua-medicine” connections=”true” suffix=””]

In Apr 2016, Hua Medicine raised $50 Mn in Series C financing, led by Harvest Investments, Frontline BioVentures; participation from existing investors, which includes ARCH, Venrock, Fidelity, WuXi Ventures, SAIL, Ally Bridge Group and TF Capital. Earlier in 2015, company raised $25 Mn in Series B Financing to start Phase 2 clinical development of its most advanced asset HMS5552 (Sinogliatin), a novel 4th-generation glucokinase activator (GKA) for Type 2 diabetes.

In Mar 2018, Hua Medicine received US$ 117.4Mn in combined series D and E financing led by Blue Pool Capital Limited, GIC Private Limited, AVICT Global, 6 Dimensions Capital, Adrian Cheng, Ping An Ventures, Mirae Asset Financial Group along with existing investors. The proceeds will help complete its two(Dorzagliatin (HMS5552), Dorzagliatin + Metformin) Phase 3 trials and commercial launch in China for Dorzagliatin (HMS5552).